Loading...

Penichet Manuel

Title(s)Professor, Microbiology Immunology & Molecular Genetics
Phone(310) 206-5126
vCardDownload vCard
    Other Positions
    Title(s)Professor, Surgery


    Collapse Research 
    Collapse Research Activities and Funding
    A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL
    NIH/NCI R01CA196266Jan 1, 2016 - Dec 31, 2020
    Role: Principal Investigator
    (PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
    NIH/NCI R21CA193953May 1, 2015 - Apr 30, 2017
    Role: Principal Investigator
    A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
    NIH/NCI R01CA181115Sep 1, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity
    NIH/NCI R01CA136841Aug 5, 2010 - May 31, 2015
    Role: Principal Investigator
    Development of an anti-PSA IgE to treat prostate cancer
    NIH/NCI R41CA137881May 1, 2009 - Jul 31, 2010
    Role: Co-Principal Investigator
    Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
    NIH/NCI R01CA107023Dec 20, 2004 - Nov 30, 2010
    Role: Principal Investigator
    Universal Vectors for the Therapy of Cancer
    NIH/NCI K01CA086915Apr 1, 2001 - Mar 31, 2007
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Daniels-Wells TR, Candelaria PV, Leoh LS, Nava M, Martínez-Maza O, Penichet ML. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication. J Immunother. 2019 Oct 30. PMID: 31693515.
      View in: PubMed
    2. Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019 08 28; 10(1):3850. PMID: 31462642.
      View in: PubMed
    3. Epeldegui M, Conti DV, Guo Y, Cozen W, Penichet ML, Martínez-Maza O. Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. Sci Rep. 2019 Jun 28; 9(1):9371. PMID: 31253857.
      View in: PubMed
    4. Luria-Pérez R, Candelaria PV, Daniels-Wells TR, Rodríguez JA, Helguera G, Penichet ML. Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein. Cytokine. 2019 Aug; 120:220-226. PMID: 31121497.
      View in: PubMed
    5. Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, Hartmann K, Josephs DH, Levi-Schaffer F, Penichet ML, O'Mahony L, Poli A, Redegeld FA, Roth-Walter F, Turner MC, Vangelista L, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper. Allergy. 2019 Jun; 74(6):1037-1051. PMID: 30636005.
      View in: PubMed
    6. Plotkin JD, Elias MG, Fereydouni M, Daniels-Wells TR, Dellinger AL, Penichet ML, Kepley CL. Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells. Front Immunol. 2019; 10:138. PMID: 30833944.
      View in: PubMed
    7. Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, Rudnick JD, Hu J, Grodzinski ZB, Rekechenetskiy A, Falahatian V, Lyubimov AV, Chen YL, Leoh LS, Daniels-Wells TR, Penichet ML, Holler E, Ljubimov AV, Black KL, Ljubimova JY. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Cancer Res. 2019 03 15; 79(6):1239-1251. PMID: 30659021.
      View in: PubMed
    8. Leoh LS, Kim YK, Candelaria PV, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol. 2018 05 15; 200(10):3485-3494. PMID: 29654211.
      View in: PubMed
    9. Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF. Virus-like particle display of HER2 induces potent anti-cancer responses. Oncoimmunology. 2018; 7(3):e1408749. PMID: 29399414.
      View in: PubMed
    10. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2017; 8:1751. PMID: 29379493.
      View in: PubMed
    11. Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Dombrowicz D, Fiebiger E, Gould HJ, Irshad S, Janda J, Josephs DH, Levi-Schaffer F, O'Mahony L, Pellizzari G, Penichet ML, Redegeld F, Roth-Walter F, Singer J, Untersmayr E, Vangelista L, Karagiannis SN. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy. 2018 02; 73(2):328-340. PMID: 28921585.
      View in: PubMed
    12. Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis SN. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy. 2017 Jun; 72(6):866-887. PMID: 28032353.
      View in: PubMed
    13. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Corrigendum to "Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1" [Mol. Immunol. 67 (2015) 407-415]. Mol Immunol. 2016 12; 80:101. PMID: 27838011.
      View in: PubMed
    14. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Cancer Res. 2016 10 01; 76(19):5822-5831. PMID: 27530328.
      View in: PubMed
    15. Daniels-Wells TR, Penichet ML. Transferrin receptor 1: a target for antibody-mediated cancer therapy. Immunotherapy. 2016 09; 8(9):991-4. PMID: 27373880.
      View in: PubMed
    16. Koru-Sengul T, Santander AM, Miao F, Sanchez LG, Jorda M, Glück S, Ince TA, Nadji M, Chen Z, Penichet ML, Cleary MP, Torroella-Kouri M. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Res Treat. 2016 07; 158(1):113-126. PMID: 27283835.
      View in: PubMed
    17. Daniels-Wells TR, Widney DP, Leoh LS, Martínez-Maza O, Penichet ML. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. J Immunother. 2015 Oct; 38(8):307-10. PMID: 26325374.
      View in: PubMed
    18. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol. 2015 Oct; 67(2 Pt B):407-15. PMID: 26232328.
      View in: PubMed
    19. Cornford EM, Hyman S, Cornford ME, Chytrova G, Rhee J, Suzuki T, Yamagata T, Yamakawa K, Penichet ML, Pardridge WM. Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes. J Drug Target. 2016; 24(1):58-67. PMID: 26133964.
      View in: PubMed
    20. Leoh LS, Daniels-Wells TR, Penichet ML. IgE immunotherapy against cancer. Curr Top Microbiol Immunol. 2015; 388:109-49. PMID: 25553797.
      View in: PubMed
    21. De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 2014 Jan 23; 16(1):R10. PMID: 24451168.
      View in: PubMed
    22. Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014 Apr; 13(4):902-15. PMID: 24448822.
      View in: PubMed
    23. Leoh LS, Morizono K, Kershaw KM, Chen IS, Penichet ML, Daniels-Wells TR. Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med. 2014 Jan-Feb; 16(1-2):11-27. PMID: 24436117.
      View in: PubMed
    24. Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet ML, Martinez-Maza O. Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. PLoS One. 2013; 8(8):e72414. PMID: 23936541.
      View in: PubMed
    25. Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release. 2013 Nov 10; 171(3):322-9. PMID: 23770212.
      View in: PubMed
    26. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer. 2013 Apr 17; 13:195. PMID: 23594731.
      View in: PubMed
    27. VanderWall K, Daniels-Wells TR, Penichet M, Lichtenstein A. Iron in multiple myeloma. Crit Rev Oncog. 2013; 18(5):449-61. PMID: 23879589.
      View in: PubMed
    28. Daniels-Wells TR, Helguera G, Rodríguez JA, Leoh LS, Erb MA, Diamante G, Casero D, Pellegrini M, Martínez-Maza O, Penichet ML. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro. 2013 Feb; 27(1):220-31. PMID: 23085102.
      View in: PubMed
    29. Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res Treat. 2012 Dec; 136(3):647-58. PMID: 23065001.
      View in: PubMed
    30. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):155-63. PMID: 22440007.
      View in: PubMed
    31. Helguera G, Jemielity S, Abraham J, Cordo SM, Martinez MG, Rodríguez JA, Bregni C, Wang JJ, Farzan M, Penichet ML, Candurra NA, Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses. J Virol. 2012 Apr; 86(7):4024-8. PMID: 22278244.
      View in: PubMed
    32. Daniels TR, Martínez-Maza O, Penichet ML. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother. 2012 Sep; 61(9):1535-46. PMID: 22193986.
      View in: PubMed
    33. Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother. 2012 Jul; 61(7):991-1003. PMID: 22127364.
      View in: PubMed
    34. Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer. 2011 Nov 02; 11:471. PMID: 22044845.
      View in: PubMed
    35. Rodríguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, Martínez-Maza O, Charles AC, Pellegrini M, Helguera G, Penichet ML. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma. 2011 Nov; 52(11):2169-78. PMID: 21870996.
      View in: PubMed
    36. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012 Mar; 1820(3):291-317. PMID: 21851850.
      View in: PubMed
    37. Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother. 2011 Jul-Aug; 34(6):500-8. PMID: 21654517.
      View in: PubMed
    38. Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. For Immunopathol Dis Therap. 2011 Apr 01; 2(2). PMID: 24286018.
      View in: PubMed
    39. Helguera G, Rodríguez JA, Luria-Pérez R, Henery S, Catterton P, Bregni C, George TC, Martínez-Maza O, Penichet ML. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J Immunol Methods. 2011 May 31; 368(1-2):54-63. PMID: 21420412.
      View in: PubMed
    40. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M, Gates M, Patil R, Penichet ML, Ljubimov AV, Black KL, Holler E, Ljubimova JY. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res. 2011 Feb 15; 71(4):1454-64. PMID: 21303974.
      View in: PubMed
    41. Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet ML, Montano RF. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg. Mol Cancer Ther. 2010 Aug; 9(8):2175-85. PMID: 20682652.
      View in: PubMed
    42. Daniels TR, Neacato II, Rodríguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 2010 Sep; 24(9):1555-65. PMID: 20574452.
      View in: PubMed
    43. Bermudez-Fajardo A, Stark AK, El-Kadri R, Penichet ML, Hölzle K, Wittenbrink MM, Hölzle L, Oviedo-Orta E. The effect of Chlamydophila pneumoniae Major Outer Membrane Protein (MOMP) on macrophage and T cell-mediated immune responses. Immunobiology. 2011 Jan-Feb; 216(1-2):152-63. PMID: 20637522.
      View in: PubMed
    44. Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol. 2010 May; 36(5):1299-307. PMID: 20372806.
      View in: PubMed
    45. Rodríguez JA, Lopez MA, Thayer MC, Zhao Y, Oberholzer M, Chang DD, Kisalu NK, Penichet ML, Helguera G, Bruinsma R, Hill KL, Miao J. Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19322-7. PMID: 19880745.
      View in: PubMed
    46. Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet ML, Chen IS. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med. 2009 Aug; 11(8):655-63. PMID: 19455593.
      View in: PubMed
    47. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009; 11(3):R36. PMID: 19531256.
      View in: PubMed
    48. De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther. 2009 May; 20(5):453-64. PMID: 19215191.
      View in: PubMed
    49. Ortiz-Sánchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 2009 Jan; 23(1):59-70. PMID: 18946492.
      View in: PubMed
    50. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother. 2009 Jun; 58(6):915-30. PMID: 18941743.
      View in: PubMed
    51. Montano RF, Penichet ML, Blackall DP, Morrison SL, Chintalacharuvu KR. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents. J Immunol Methods. 2009 Jan 01; 340(1):1-10. PMID: 18848836.
      View in: PubMed
    52. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008 Oct; 63(10):1255-66. PMID: 18671772.
      View in: PubMed
    53. Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther. 2008 May; 8(5):609-32. PMID: 18407765.
      View in: PubMed
    54. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol. 2008 May 01; 180(9):6199-210. PMID: 18424742.
      View in: PubMed
    55. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther. 2008 Mar; 7(3):721-9. PMID: 18347157.
      View in: PubMed
    56. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol. 2008; 2008:723539. PMID: 18551190.
      View in: PubMed
    57. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther. 2007 Nov; 6(11):2995-3008. PMID: 18025284.
      View in: PubMed
    58. Rodríguez JA, Helguera G, Daniels TR, Neacato II, López-Valdés HE, Charles AC, Penichet ML. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release. 2007 Dec 04; 124(1-2):35-42. PMID: 17884229.
      View in: PubMed
    59. Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, Ding H, Holler E, Black KL, Ljubimova JY. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release. 2007 Oct 08; 122(3):356-63. PMID: 17630012.
      View in: PubMed
    60. Helguera G, Rodríguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunol Immunother. 2007 Sep; 56(9):1507-12. PMID: 17310381.
      View in: PubMed
    61. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007 May 01; 109(9):3915-21. PMID: 17213289.
      View in: PubMed
    62. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006 Nov; 121(2):159-76. PMID: 16920030.
      View in: PubMed
    63. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006 Nov; 121(2):144-58. PMID: 16904380.
      View in: PubMed
    64. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006 Oct 15; 108(8):2745-54. PMID: 16804109.
      View in: PubMed
    65. Helguera G, Rodríguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther. 2006 Apr; 5(4):1029-40. PMID: 16648575.
      View in: PubMed
    66. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol. 2006 Feb; 43(6):667-76. PMID: 15908002.
      View in: PubMed
    67. Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine. 2005 Sep 15; 23(39):4793-803. PMID: 15967544.
      View in: PubMed
    68. Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine. 2006 Jan 16; 24(3):304-16. PMID: 16125282.
      View in: PubMed
    69. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther. 2005 Jun; 4(6):956-67. PMID: 15956253.
      View in: PubMed
    70. Helguera G, Penichet ML. Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med. 2005; 109:347-74. PMID: 15585931.
      View in: PubMed
    71. Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng. 2005 Feb; 21(6):145-55. PMID: 15748688.
      View in: PubMed
    72. Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med. 2004 Oct; 4(2):57-64. PMID: 15672942.
      View in: PubMed
    73. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine. 2003 Mar 28; 21(13-14):1317-26. PMID: 12615426.
      View in: PubMed
    74. Helguera G, Morrison SL, Penichet ML. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol. 2002 Dec; 105(3):233-46. PMID: 12498805.
      View in: PubMed
    75. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10706-11. PMID: 12149472.
      View in: PubMed
    76. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. Myeloma expression systems. J Immunol Methods. 2002 Mar 01; 261(1-2):1-20. PMID: 11861062.
      View in: PubMed
    77. Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). J Interferon Cytokine Res. 2001 Sep; 21(9):709-20. PMID: 11576465.
      View in: PubMed
    78. Penichet ML, Dela Cruz JS, Challita-Eid PM, Rosenblatt JD, Morrison SL. A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Cancer Immunol Immunother. 2001 Feb; 49(12):649-62. PMID: 11258791.
      View in: PubMed
    79. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods. 2001 Feb 01; 248(1-2):91-101. PMID: 11223071.
      View in: PubMed
    80. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies. 2001; 10(1):43-9. PMID: 11455061.
      View in: PubMed
    81. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol. 2000 Nov 01; 165(9):5112-21. PMID: 11046042.
      View in: PubMed
    82. Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin SU. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J Immunol. 1999 Oct 15; 163(8):4421-6. PMID: 10510383.
      View in: PubMed
    83. Peng LS, Penichet ML, Morrison SL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol. 1999 Jul 01; 163(1):250-8. PMID: 10384123.
      View in: PubMed
    84. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci. 1999 Apr; 49(2):179-88. PMID: 10331548.
      View in: PubMed
    85. Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V, Rosenblatt JD. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol. 1998 Oct 01; 161(7):3729-36. PMID: 9759898.
      View in: PubMed
    86. Penichet ML, Harvill ET, Morrison SL. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J Interferon Cytokine Res. 1998 Aug; 18(8):597-607. PMID: 9726441.
      View in: PubMed
    87. Challita-Eid PM, Penichet ML, Shin SU, Poles T, Mosammaparast N, Mahmood K, Slamon DJ, Morrison SL, Rosenblatt JD. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol. 1998 Apr 01; 160(7):3419-26. PMID: 9531302.
      View in: PubMed
    88. Penichet ML, Harvill ET, Morrison SL. Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies. 1997; 8(3):106-18. PMID: 9322080.
      View in: PubMed